ArticleFrontiers in microbiology2025
Evaluation of PhenoMATRIX® PLUS for the culture-based rectal screening of CPOs, ESBL-E,
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Epidemiological and Molecular Surveillance of Multiresistant Citrobacter freundii Complex in a Tertiary Care Hospital: A Retrospective Cohort Study.The Journal of infectious diseases · 2026Article
- [Advances in integrated antimicrobial resistance diagnostics: quantitative, qualitative and AI-driven approaches].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2026Review
- Total laboratory automation-based monitoring processes: setup and validation of an integrated internal quality control panel.Frontiers in cellular and infection microbiology · 2026Article
- Evolving microbiology laboratories: mastering automated culture-based processes and molecular assays, an institutional experience.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multidrug-resistant organisms (MDROs) have become a serious public health concern worldwide. Screening for MDROs can encompass various phenotypic and genotypic approaches. Recently, culture-based MDROs screening has substantially benefitted from laboratory automation and artificial intelligence. Objectives: To evaluate the performance of PhenoMATRIX® PLUS for an institution-wide culture-based rectal screening for CPOs, ESBL-E, Methods: The number of non-duplicated rectal Eswabs specimens used to generate culture plate images for the PhenoMATRIX® PLUS machine learning phase amounted to 2'900 for chromID™ ESBL agar, 2'403 for chromID™ OXA-48 agar, 2'031 for CHROMagar™ Results: According to the manual work-up results, the output agreements of the PhenoMATRIX® PLUS for the three results " Conclusion: PhenoMATRIX® PLUS contributes to a significant reduction in the workload. Therefore, technologists' routine tasks have evolved to the confirmatory tests of the presumptively positive colonies, allowing better management of the laboratory staff and the resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.